2006•Medical InformationRequires access

Valsartan for the treatment of early clinical diabetic nephropathy

Xu AiGuo

Abstract

Objective To observe the effect of Valsartan on the early type 2 diabetic nephropathy with UAER. Method 49 cases of type 2 diabetes mellitus with nephropathy were divided into two groups at random: one was normal control group (n=24), the other was given Valsartan 80mg qd (n=25) respectively without changing the previous management of DM. After 12 weeks of treatment the changes of UAER was observed. Result In the control group the UAER changed significantly (P0.05). Conclusion AT1 Ra Valsartan is effectively reducing the micro albumin excretion in the early diabetic nephropathy and thus protect the kidney.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Valsartan, Medicine, Diabetic nephropathy, Urology, Diabetes mellitus, Excretion, Internal medicine, Nephropathy